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a  b  s  t  r  a  c  t
1-Antitrypsin  is  primarily  synthesised  in the  liver,  circulates  to  the  lung  and protects  pulmonary  tis-
sues  from  proteolytic  damage.  The  Z mutant  (Glu342Lys)  undergoes  inactivating  conformational  change
and polymerises.  Polymers  are  retained  within  the  hepatocyte  endoplasmic  reticulum  (ER) in homozy-
gous  (PiZZ) individuals,  predisposing  the  individuals  to  hepatic  cirrhosis  and  emphysema.  Latency  is
an analogous  process  of inactivating,  intra-molecular  conformational  change  and  may  co-occur  with
polymerisation.  However,  the  relationship  between  latency  and  polymerisation  remained  unexplored  in
the absence  of  a suitable  probe.  We  have  developed  a  novel  monoclonal  antibody  speciﬁc  for  latent
1-antitrypsin  and  used  it in combination  with  a polymer-speciﬁc  antibody,  to  assess  the  associa-
tion  of  both  conformers  in vitro,  in disease  and  during  augmentation  therapy.  In vitro  kinetics  analysis
showed  polymerisation  dominated  the pathway  but  latency  could  be  promoted  by stabilising  monomeric
1-antitrypsin.  Polymers  were  extensively  produced  in  hepatocytes  and  a cell  line expressing  Z 1-
antitrypsin  but the latent  protein  was  not  detected  despite  manipulation  of  the  secretory  pathway.
However,  1-antitrypsin  augmentation  therapy  contains  latent  1-antitrypsin,  as  did the  plasma  of
63/274  PiZZ  individuals  treated  with  augmentation  therapy  but 0/264  who  were  not receiving this  medi-
−14cation  (p <  10 ). We  conclude  that  latent  1-antitrypsin  is  a by-product  of  the polymerisation  pathway,
that  the  intracellular  folding  environment  is  resistant  to  formation  of  the  latent  conformer  but that  aug-
mentation  therapy  introduces  latent  1-antitrypsin  into  the  circulation.  A  suite  of  monoclonal  antibodies
and  methodologies  developed  in  this  study  can  characterise  1-antitrypsin  folding  and conformational
transitions,  and screen  method
© 2014  The  Authors.  Publis
∗ Corresponding author at: University College London, 1st Floor Maple House, 149,
ottenham Court Road, London W1T  7NF, UK. Tel.: +44 0 20 3108 2105;
ax: +44 0 20 7679 0876.
∗∗ Corresponding author at: Division of Asthma, Allergy and Lung Biology, King’s
ollege London, Guy’s Hospital, 5th Floor, Tower Wing, London, UK.
el.: + 44 (0)20 7188 0599; fax: +44 (0)20 7188 3632.
E-mail addresses: bibek.gooptu@kcl.ac.uk (B. Gooptu), d.lomas@ucl.ac.uk
D.A. Lomas).
ttp://dx.doi.org/10.1016/j.biocel.2014.11.005
357-2725/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article us  to  improve  augmentation  therapy.
hed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
1-Antitrypsin is a member of the serine protease inhibitor (ser-
pin) superfamily. It is predominantly synthesised in hepatocytes
and circulates to the lung where it functions to protect the pul-
monary tissue from proteolytic damage by inhibiting the enzyme
neutrophil elastase (Fig. 1A). Individuals carrying two wild-type
M alleles that encode functional 1-antitrypsin are denoted PiMM
(Lomas et al., 1992; Perlmutter, 2004; Stoller and Aboussouan,
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. Function of ˛1-antitrypsin and structures of its conformers. (A) The structure
of  1-antitrypsin (native) is based on three -sheets (purple), nine -helices and a
ﬂexible reactive centre loop (green) that is recognised as a pseudosubstrate by neu-
trophil elastase (Elliott et al., 1998) (complex). Upon binding, the reactive centre
loop  of 1-antitrypsin is cleaved and incorporated into -sheet A. This translo-
cates neutrophil elastase from the upper to the lower pole of the protein which
distorts the catalytic site and inactivates the enzyme. Interaction of 1-antitrypsin
with a non-target protease results in the cleaved conformer in which the reactive
loop is cleaved and inserted into -sheet A without the formation of an inhibitory
complex (cleaved). (B) Major conformations of 1-antitrypsin include the native
(Nat), cleaved (Clv), polymeric (Pol) and latent (Lat) forms. Different models for the
structure of the polymer have been proposed (Carrell et al., 1994; Dafforn et al.,
1999; Ekeowa et al., 2010; Gooptu et al., 2000; Haq et al., 2013; Lomas et al., 1992;
McGowan et al., 2006; Sharp et al., 1999; Yamasaki et al., 2008, 2011; Zhang et al.,
2008) including the classical model, as shown (Pol), in which the reactive centre
loop  of one molecule is incorporated into the open -sheet A of another molecule.
The latent conformer (Lat) features the insertion of the reactive centre loop into the
same molecule. The cleaved, polymeric and latent conformations have no inhibitory
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Puriﬁed latent  -antitrypsin was prepared (Lomas et al., 1995)ctivity. (For interpretation of the references to color in this ﬁgure legend, the reader
s  referred to the web version of this article.)
012). The Z allele of 1-antitrypsin (Glu342Lys) causes 85-90%
f the protein to misfold, undergo inactivating conformational
hange and either be degraded or form polymers that are retained
ithin hepatocytes. The gain-of-function toxicity of polymeric 1-
ntitrypsin causes liver damage with nearly half of 1-antitrypsin
eﬁcient adults over the age of 50 having features of liver cirrhosis
nd occasionally hepatocellular carcinoma (Eriksson et al., 1986).
he concomitant lack of circulating 1-antitrypsin predisposes PiZZ
omozygotes to early onset emphysema.
Polymerisation of Z 1-antitrypsin is a central event in the
athogenesis of 1-antitrypsin deﬁciency. It arises through aber-
ant structural behaviour within the  -antitrypsin molecule1
hat subverts a process of conformational change that is essential
or normal function (Fig. 1B). Polymeric 1-antitrypsin is found
ithin the Periodic Acid Schiff (PAS) positive inclusion bodies inemistry & Cell Biology 58 (2015) 81–91
hepatocytes (Ekeowa et al., 2010; Eriksson et al., 1986; Miranda
et al., 2010). Polymers of 1-antitrypsin are also present in the
circulation of PiZZ individuals (Janciauskiene et al., 2002; Schmid
et al., 2012; Tan et al., 2014) and have been detected in the lung,
kidney and skin (Elliott et al., 1998; Gross et al., 2009; Lawless
et al., 2004; Mahadeva et al., 2005; Morris et al., 2011; Paakko
et al., 1996; Venembre et al., 1994). The structure of the polymers
that form within hepatocytes has been the subject of much debate.
Several models of polymerisation have been proposed including
the classical reactive centre loop--sheet A linkage (Fig. 1B, Pol)
ﬁrst proposed in 1992 (Dafforn et al., 1999; Ekeowa et al., 2010;
Gooptu et al., 2000; Haq et al., 2013; Lomas et al., 1992); linkage via
-sheet C (Carrell et al., 1994; Zhang et al., 2008); an extra, lateral
strand of -sheet A (s7A) (McGowan et al., 2006; Sharp et al.,
1999); -hairpin (Yamasaki et al., 2008) and C-terminal (Yamasaki
et al., 2011) domain swaps. Studies using the polymer-speciﬁc 2C1
monoclonal antibody (MAb) have shown that there are multiple
forms of polymer depending on the conditions used to generate
the polymer in vitro (Ekeowa et al., 2010; Miranda et al., 2010).
Serpins can adopt the inactive but intact monomeric latent con-
formation in which the reactive centre loop is inserted into the
underlying -sheet A in the absence of proteolytic cleavage (Fig. 1B,
Lat). The principle models of serpin polymerisation relate forma-
tion of the latent conformer to polymerisation in different ways. In
the “classical” (reactive centre loop--sheet A insertion) model of
serpin polymerisation, the latent conformer is an alternative prod-
uct of the pathway that leads to polymerisation. Intra-molecular
(Fig. 1B, Lat) and inter-molecular (Fig. 1B, Pol) loop insertion lead
to the formation of latent and polymeric 1-antitrypsin, respec-
tively. The -hairpin model (Yamasaki et al., 2008) suggests no
relationship between a native-latent pathway and polymerisation.
Conversely, the C-terminal domain swap model (Yamasaki et al.,
2011) suggests that the latent state may  be an intermediate prior
to polymer formation. Indeed, neuroserpin, another member of the
serpin superfamily associated with encephalopathy and demen-
tia, is able to readily polymerise from a latent conformation (Onda
et al., 2005). The latent conformer has also been reported in other
members of the serpin superfamily, including plasminogen acti-
vator inhibitor-1 (PAI-1) (Fjellstrom et al., 2013), antithrombin
(Chang and Lomas, 1998; Corral et al., 2007; Laschke et al., 2004;
Mushunje et al., 2004) and 1-antichymotrypsin (Gooptu et al.,
2000). However, latency in 1-antitrypsin and its association with
polymerisation remained unexplored in the absence of a suitable
probe.
We report the development of a conformer-speciﬁc MAb  (1C12)
for latent 1-antitrypsin, and describe a robust methodology for
using it to demonstrate and quantify levels of latent 1-antitrypsin
in biological samples. Moreover, we  have used the 1C12 MAb  in
combination with the polymer-speciﬁc 2C1 antibody to assess the
association of the latent and polymeric conformers in vitro, in dis-
ease and during augmentation therapy. We  have characterised the
association of latency and polymerisation: (i) with in vitro kinetic
studies using puriﬁed proteins; (ii) in a cell model of 1-antitrypsin
deﬁciency; (iii) in biological samples of human liver; (iv) in human
plasma and (v) in therapeutic preparations of 1-antitrypsin.
2. Materials and methods
2.1. Generation of monoclonal antibodies speciﬁc for the latent
conformer of ˛1-antitrypsin1
and used to immunise mice. Mouse spleen cells were isolated
and hybridised with myeloma cells to generate hybridomas as
described previously (Irving et al., 2011; Miranda et al., 2008).
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Table 1
Assessment of ﬁbrosis grade, polymer score and the presence of latent 1-
antitrypsin in liver tissue from individuals with a range of 1-antitrypsin genotypes.
Sample No. Genotype Fibrosis grade Polymer Score (%) Latent (+/−)
1 MM 0 – −
2  MM 0 – −
3  MS  6 5 −
4  FZ 6 18 −
5  MZ  6 29 −
6  MZ  6 26 −
7  MZ  6 13 −
8  MZ  6 8 −
9  MZ  6 35 −
10  MZ  6 5 −
11  MZ  6 26 −
12  MZ  6 18 −
13  MZ  2 18 −
14  MZ  6 60 −
15  MZ  6 3 −
16  MZ  6 18 −
17  MZ  6 10 −
18  MZ  6 7 −
19  MZ  6 0.4 −
20  MZ  6 14 −
21  SZ 1 18 −
22  SZ 6 17 −
23  ZZ 6 69 +
24  ZZ 6 33 +
25  ZZ 6 59 +
26  ZZ 1 43 −
27  ZZ 1 11 −
28  ZZ 2 4 −
29  ZZ 1 3 −
30  ZZ 6 15 +
31  ZZ 6 14 +L. Tan et al. / The International Journal o
terative cloning and enzyme-linked immunosorbent assay (ELISA)
ere used to select hybridoma clones that produced antibodies
hat were speciﬁc for latent 1-antitrypsin. Several classes of anti-
odies with different binding speciﬁcities were identiﬁed, with the
ost interesting being the 1C12 that speciﬁcally recognised latent
1-antitrypsin. MAb  1F10 was identiﬁed that recognised both the
atent and cleaved conformers of 1-antitrypsin. This antibody was
sed in combination with 1C12 in sandwich ELISA for quantifying
he latent conformer (Supplementary Fig. 1).
.2. Protein sample handling, gel electrophoresis and western blot
Plasma puriﬁed native M and Z 1-antitrypsin (Lomas et al.,
993) were stored in −80 ◦C and handled on ice for experiments.
or ELISA and western blot analysis, cell and serum samples were
lso processed on ice. Non-denaturing (3–12% NativePAGE Bis–Tris
el) and SDS-PAGE (NuPAGE Bis–Tris, both from Life Technologies)
els were used to separate the samples. 6 M urea gel was  prepared
ith 8% acrylamide (w/v) and 0.375 M Tris buffer. In western blot
nalysis, proteins were transferred onto nitrocellulose-membranes
hat were then blocked with buffer containing PBS, 0.05% Tween-20
v/v), 5% skim-milk (w/v) and then incubated with the primary anti-
ody in TBS (0.05% Tween-20 (v/v), 5% BSA (w/v)) overnight. The
embranes were incubated with HRP-labelled secondary antibody
or 1 h in blocking buffer and developed using enhanced chemi-
uminescence (Thermo Scientiﬁc, Rockford, IL USA)
.3. MAb  studies of polymer and latent formation in vitro
Plasma puriﬁed native M and Z 1-antitrypsin (Lomas et al.,
993) were incubated at 200 g/ml in 20 mM Tris buffer, pH
.4, with and without sodium citrate (0.7 M).  M and Z 1-
ntitrypsin were heated at 48 ◦C and 40 ◦C, respectively. The choice
f temperature was determined by temperature gradient analy-
is (Supplementary Fig. 3). Incubations were monitored by taking
amples for analysis every 12 h (from 0 to 108 h, 10 data points).
amples were analysed by non-denaturing and 6 M urea PAGE, and
uantiﬁed by sandwich ELISA using the 2C1 antibody for polymers
Ekeowa et al., 2010; Miranda et al., 2010) and the 1C12 antibody
or latent 1-antitrypsin.
.4. MAb  detection of polymeric and latent ˛1-antitrypsin
eﬁciency in a cell model
Chinese hamster ovary (CHO) cells were stably transfected to
xpress M or Z 1-antitrypsin (Ordonez et al., 2013). The expression
f 1-antitrypsin was induced by 1 g/ml doxycycline (dox), and
ells were cultured for 144 h (six days) before the detection of latent
r polymeric 1-antitrypsin. The cells were also cultured with 0.5,
, 2, 5, 10 or 20 g/ml Brefeldin A, an inhibitor of endoplasmic
eticulum (ER) to Golgi transport, for 30, 60, 90, 120 and 240 min.
urthermore, a range of compounds (in combination or separately)
as used that interfere with different cellular pathways: tuni-
amycin (2.5 g/ml), thapsigargin (250 nM)  (each in the absence
nd presence of 5 M lactacystin), and with 5 M lactacystin alone.
unicamycin and thapsigargin induce protein misfolding and ER
tress, whereas lactacystin inhibits proteasome function. Media
nd/or cell lysates were collected from each condition, and ana-
ysed by ELISA for the presence or absence of polymeric and latent
1-antitrypsin.
.5. Immunohistochemistry of human liver sectionsFormalin-ﬁxed, parafﬁn embedded human liver tissues were
vailable from 30 individuals across a range of genotypes (Table 1)
nd two control samples. These were explants or biopsies from32  ZZ 1 4 −
individuals undergoing investigation for 1-antitrypsin deﬁciency
in a tertiary referral centre. Twenty-three individuals had cirrhosis
(Ishak (Ishak et al., 1995; Standish et al., 2006) stage 6) and seven
had minimal ﬁbrosis (Ishak stage 1 or 2). Unless speciﬁed, all
steps were performed at room temperature. The tissue slides
were deparafﬁnised by serial incubation in xylene and decreasing
concentration of ethanol. Antigen was retrieved by 10 mM sodium
citrate buffer pH 6.0 at sub-boiling temperature for 10 min. For ﬂuo-
rescence microscopy, tissue slides were incubated overnight at 4 ◦C
with two  primary antibodies simultaneously, an in-house rabbit
polyclonal antibody (2 g/ml) that detects all conformers of 1-
antitrypsin and the mouse MAb  1C12 (1:10 dilution of hybridoma
cell culture medium) that is speciﬁc for latent 1-antitrypsin. This
was followed by incubation with an anti-rabbit secondary antibody
conjugated with tetramethyl rhodamine isothiocyanate (2 g/ml),
and an anti-mouse secondary antibody conjugated with ﬂuorescein
isothiocyanate (FITC, 2 g/ml) for 1 h (both from Abcam, Cam-
bridge, UK). A second liver tissue slide from the same individual was
processed using the same procedure but stained with 2C1 instead
of 1C12, for detection of polymeric 1-antitrypsin (Miranda et al.,
2010). Tissue slides were viewed with a Carl Zeiss Laser Scanning
Microscope 510 (Carl Zeiss Inc., Jena, Germany). For the bright-ﬁeld
microscopy, after deparafﬁnisation and antigen-retrieval, tissue
slides were incubated overnight at 4 ◦C with one primary antibody,
1C12 or 2C1 on adjacent tissue slides from the same subject.
Tissues were then processed with 0.3% (v/v) hydrogen peroxide,
followed by incubation for 1 h with a secondary anti-mouse anti-
body labelled with horseradish peroxidase (HRP) and developed
with diaminobenzidine (DAB, both from Sigma-Aldrich Co., Dorset,
UK). The concentration of the antibodies used was  the same as in
the ﬂuorescence microscopy. Tissue slides were counter-stained
with Harris haematoxylin (Sigma-Aldrich Co., Dorset, UK) and
viewed with a Zeiss Axioskope II (Carl Zeiss Inc., Jena, Germany)
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icroscope. Polymer scores were determined using Image J
Schneider et al., 2012), by segmenting the polymer staining sig-
als of the 2C1 antibody and measuring the fraction of the isolated
rea containing positive signals versus the total area analysed
embedded function of Image J, standard processing of immuno-
istochemistry staining). Regions for measurement were selected
t random. Since samples contained little latent 1-antitrypsin, a
inary system (+/−) was used to assess the presence or absence of
his conformer.
.6. Immunoprecipitation and analysis of augmentation therapy
Immunoprecipitation (Tan et al., 2014) was carried out to con-
rm the ability of 1C12 to speciﬁcally detect latent 1-antitrypsin
n plasma samples. Sepharose G beads were incubated with the
C12 MAb  and then with 1 l of a plasma sample containing latent
1-antitrypsin as well as a plasma sample containing no latent
1-antitrypsin. A positive control of puriﬁed latent 1-antitrypsin,
nd three negative controls of immunoprecipitation with no added
lasma, blotting of sepharose G beads and the 1C12 antibody
ere also included. The immunoprecipitated protein was  eluted
y dithiothreitol (DTT), and separated by SDS-PAGE followed by
estern blot analysis using the rabbit polyclonal antibody to detect
1-antitrypsin. A commercial preparation of augmentation ther-
py (Prolastin, Talecris Biotherapeutics Inc., North Carolina, US) was
econstituted according to manufacturer’s instructions and diluted
o 1 mg/ml  stock for electrophoresis and western blot analysis.
.7. ELISA screening of human plasma samples
811 Plasma samples (518 from the Alpha-1 Antitrypsin Genetic
odiﬁer Study (Demeo et al., 2007) and 293 from the Alpha-1
oundation DNA and Tissue Bank) (Tan et al., 2014) of mixed 1-
ntitrypsin genotypes (number): MM (200), MZ  (20), ZZ (538), SZ
20), FZ (5), SS (3), MS  (20), ZMheerlen (3) and ZMmalton (2),
ere analysed by ELISA (Cohort I). A further cohort of 116 plasma
amples from the Alpha-1 Foundation DNA and Tissue Bank with
nformation on augmentation therapy was also examined (Cohort
I). The augmentation therapy used in Cohorts I and II was Pro-
astin. Furthermore, 24 and 33 samples from individuals receiving
wo other augmentation drugs, Aralast and Zemaira, were also ana-
ysed (Supplement Table 1). The screening analysis was  composed
f two steps: (i) a qualitative assay to determine the presence or
bsence of latent 1-antitrypsin; (ii) positive samples detected in
i) were further processed in a quantitative assay to determine
he amount of latent 1-antitrypsin present. Brieﬂy, in step (i)
he plates were coated overnight with 2 g/ml antigen puriﬁed
abbit polyclonal 1-antitrypsin antibody. Standard puriﬁed latent
1-antitrypsin (positive control) and subject samples were diluted
n blocking buffer (1:200 for plasma samples) and incubated for
 h. The wells were washed and incubated with the 1C12 MAb
ulture medium supernatant diluted in blocking buffer (1:50) for
 h. Bound 1C12 antibody was detected with anti-mouse antibody
abelled with HRP, and the reaction was developed with 3,3′,5,5′-
etramethylbenzidine (TMB) substrate solution (Sigma-Aldrich Co.,
orset, UK) and stopped with 1 M sulfuric acid. Absorption at
50 nm was measured using a plate reader (Molecular Devices,
hermo-max microplate reader). This assay distinguished between
latent-positive” and “latent-negative” samples, but its use in quan-
ifying latent 1-antitrypsin was restricted by the limited linearity
f the standard curve. Therefore, a quantitative assay with good
inearity in regression analysis was developed using two  mono-
lonal antibodies, 1F10 and 1C12 (Supplementary Fig. 1). Samples
hat gave a positive signal for latent 1-antitrypsin were ana-
ysed in step (ii) in which the plates were coated with 5 g/ml
F10 MAb  that binds both latent and cleaved 1-antitrypsin. Serialemistry & Cell Biology 58 (2015) 81–91
dilutions of puriﬁed latent 1-antitrypsin (standard curve) and
plasma samples diluted (1:2000) in blocking buffer, were incubated
for 2 h, followed by detection using 0.5 g/ml puriﬁed 1C12 anti-
body directly conjugated with HRP. The conjugation was  carried
out using EZ-link plus activated peroxidase kit (Thermo Fisher Sci-
entiﬁc, Cramlington, UK). Reaction development and plate reading
were the same as in step (i). The latent 1-antitrypsin concen-
trations were determined by regression analysis from standard
curves.
2.8. Statistical analysis
The ELISA characterisation of monoclonal antibodies, in vitro
kinetic dynamics of polymer and latent 1-antrypsin and the cell
experiments were repeated three times. Data are presented with
standard error of the mean (SEM). For the polymer scoring 20
images were analysed per biopsy sample, and the mean values of
area fraction were recorded. The relation between levels of total
and latent 1-antitrypsin was ﬁtted using the linear function in
EXCEL and the quality of ﬁtting (R2, values close to 1 indicate good
correlation) was  calculated as the square of the Pearson product
moment correlation coefﬁcient.
2.9. Ethical approval
The study was approved by local Institutional Review Boards
and all subjects provided informed consent.
3. Results and discussion
3.1. Development of conformer-speciﬁc monoclonal antibodies
Immunisation of mice with puriﬁed latent 1-antitrypsin, and
the screening of hybridoma cell lines derived from the mouse
spleen cells, led to the identiﬁcation of the 1C12 MAb  that specif-
ically recognised the latent conformer of 1-antrypsin (Fig. 2).
In both antigen and sandwich ELISAs, the 1C12 MAb  detected
only the latent conformer and no other conformations includ-
ing the native, cleaved and polymeric forms of 1-antitrypsin
(Fig. 2B and C). Two  control MAbs were included: 3C11 that
detects all conformers of 1-antitrypsin and the previously char-
acterised 2C1 antibody that detects only polymers (Miranda
et al., 2010). MAb  recognition of 1-antitrypsin conformers was
also assessed by non-denaturing PAGE and western blot analy-
sis (Fig. 2D), which yielded results that were consistent with the
data from the ELISAs. Importantly, the binding speciﬁcity of the
1C12 MAb  to the latent form of the Z mutant is the same as
observed for the latent form of M 1-antitrypsin (Supplementary
Fig. 2).
3.2. MAb  studies of ˛1-antitrypsin latency and polymerisation
in vitro
The availability of the conformer-speciﬁc antibodies allowed the
investigation of the formation of 1-antitrypsin conformers in vitro.
This was  studied in a time course by incubating puriﬁed native
monomeric M and Z 1-antitrypsin at equivalent polymerogenic
temperatures (Supplementary Fig. 3) with and without sodium
citrate. In the absence of sodium citrate, M and Z 1-antitrypsin
formed both polymeric and latent conformers (Fig. 3A and B).
Levels of the latent conformer were low and stabilised relatively
early while polymer levels increased steadily over time. Sodium
citrate stabilises the monomeric form of 1-antitrypsin and favours
the pathway to latent 1-antitrypsin (Lomas et al., 1995). In the
presence of sodium citrate, the polymerisation pathway was sig-
niﬁcantly inhibited, resulting in dominant production of the latent
L. Tan et al. / The International Journal of Biochemistry & Cell Biology 58 (2015) 81–91 85
Fig. 2. Development of MAbs. (A) Development procedure of MAbs. (B) Validation of MAbs speciﬁcity by antigen ELISA. The 3C11 and 2C1 MAbs were included as controls. The
3C11  MAb  binds to all conformers of 1-antitrypsin whilst the 2C1 MAb recognises only the polymeric conformer as previously described (Miranda et al., 2010). The 1C12
M  Valid
w s to th
c
k
w
l
f
oAb  was  identiﬁed that recognised only the latent conformer of 1-antitrypsin. (C)
ith  the 3C11, 2C1 and 1C12 MAbs respectively. The binding speciﬁcity of the MAb
onformer for both M and Z 1-antitrypsin (Fig. 3C and D). The
inetics and relative quantities of the two conformers produced
ithout manipulating the pathways (Fig. 3A and B) imply that the
atent conformer is unlikely to be a direct precursor of polymers
ormed in these non-denaturing conditions, but rather a by-product
f the polymerisation pathway.ation of MAbs by sandwich ELISA. (D) Western blot analysis of non-denaturing gels
e protein conformers was consistent in (B)–(D). Results are n = 3 with SEM.
3.3. Polymeric, but not latent, ˛1-antitrypsin was inducible in a
cell model of ˛1-antitrypsin deﬁciencyWe investigated the formation of polymeric and latent con-
formers in a cell model of 1-antitrypsin deﬁciency. CHO cells
were stably transfected to produce comparable levels of total M
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Fig. 3. MAb  studies of ˛1-antitrypsin polymerisation and latency in vitro. Native M and Z variants of 1-antitrypsin (200 g/ml) were heated with or without sodium citrate at 48
a ◦ A) M 
( . Sam
a sidua
a 12 for
a
w
C
mnd  40 C, respectively. Samples were taken every 12 h for analysis from 0 to 108 h. (
C)  M 1-antitrypsin, with sodium citrate. (D) Z 1-antitrypsin, with sodium citrate
 urea PAGE (middle) for separation of the latent conformer as the latent and the re
nd  in sandwich ELISA (right) using the 2C1 MAb for detecting the polymer and 1Cnd Z 1-antitrypsin (Ordonez et al., 2013). The cells were treated
ith a range of compounds in combination or separately (Fig. 4).
HO cells expressing Z 1-antitrypsin form intracellular poly-
ers and provide a model system for studying ER overload and1-antitrypsin, without sodium citrate. (B) Z 1-antitrypsin, without sodium citrate.
ples were analysed by non-denaturing PAGE (left) for visualisation of polymers, on
l native conformers had a similar migration on a non-denaturing gel (left, Nat/Lat),
 the latent conformer. Results are n = 3 with SEM.cellular pathways of polymerisation. Brefeldin A was used to block
ER-Golgi transport to increase the amount of protein in the ER
and so induce formation of latent 1-antitrypsin. Tunicamycin
and thapsigargin were used to induce protein misfolding and ER
L. Tan et al. / The International Journal of Bioch
Fig. 4. Polymer was inducible in a cell model of Z ˛1-antitrypsin deﬁciency, whilst latent
˛1-antitrypsin was not detected. CHO cells were stably transfected to express M (wild-
type) or Z (mutant) 1-antitrypsin and expression was induced with doxycycline
(dox) (Ordonez et al., 2013). ELISA assays were used to quantify the latent and poly-
meric 1-antitrypsin. Three different experiments were performed: (A) induction
of  M and Z 1-antitrypsin with dox. Cell culture media (med) and cell lysates (lys)
were collected after 144 h (six days). There was  no detectable latent 1-antitrypsin
(data not shown), whilst abundant polymers were detected in the Z cells. (B) Cells
were treated with brefeldin A (BFA, 5 g/ml). BFA was dissolved in dmso and so
a  solvent control was included (column 2). No polymers or latent 1-antitrypsin
were detected in cells expressing M 1-antitrypsin and no latent 1-antitrypsin was
detectable in cells expressing Z 1-antitrypsin (data not shown). The ﬁgure shows
polymer levels in the Z cell lysates. (C) CHO cells that express Z 1-antitrypsin were
treated with combinations of tunicamycin (Tm), thapsigargin (Tg ) and lactacystin
(Lc) as described in the methods section. Two protocols were used to administer the
compounds: (i) cells were ﬁrst treated with the compounds for 4 h, followed by the
addition of dox and incubation for a further 12 h; (ii) cells were ﬁrst treated with
dox  for 7 h followed by addition of the compounds and incubation of a further 12 h.
T
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samples implies that latent 1-antitrypsin does not accumulatehese two protocols are denoted (i) and (ii). Media (med) and cell lysates (lys) were
nalysed for latent (negative, data not shown) and polymeric 1-antitrypsin. N.D.:
ot detected. Results are n = 3 with SEM.
tress to assess whether latent 1-antitrypsin might arise when
haperones were diverted to process misfolded proteins. Lacta-
ystin was used to block the proteasome to assess whether latent
1-antitrypsin might arise when degradation was inhibited. How-
ver in no case was latent 1-antitrypsin detected in ELISA assaysemistry & Cell Biology 58 (2015) 81–91 87
despite there being high concentrations of polymers (Fig. 4B and
C). The presence of both polymeric and latent conformers in vitro
and the absence of latent 1-antitrypsin in the cell model imply
that cells may  not produce latent 1-antitrypsin even when kinetic
constraints are removed. This suggests that the native conformer
is chaperoned or thermodynamically stabilised by some mech-
anism within the ER milieu. Alternatively the latent state may
be produced at very low levels (compared to polymers) and efﬁ-
ciently cleared by a more speciﬁc cellular mechanism that was
not inhibited in these experiments. Since the production of the
latent 1-antitrypsin signiﬁcantly increased when the polymeri-
sation pathway was inhibited (sodium citrate, Fig. 3C and D) in the
cell-free in vitro condition, cell permeating polymerisation block-
ers for drug design might by analogy increase intracellular latent
1-antitrypsin.
3.4. Distribution patterns of polymeric and latent ˛1-antitrypsin
in liver tissue
Liver tissue samples from 30 individuals with ﬁve different 1-
antitrypsin genotypes (Table 1) and two  PiMM control samples
were analysed by immunohistochemistry and confocal microscopy.
None of these individuals were receiving 1-antitrypsin augmen-
tation therapy. The staining showed that polymers were most
commonly located in the periportal zone in close proximity to por-
tal tract ﬁbrous tissue, forming ring-like patterns (Fig. 5A). High
power images revealed that hepatocytes containing the greatest
concentration of polymers were almost always in close proxim-
ity to ﬁbroblasts. Whilst polymer was detected in tissue samples
from all individuals who were homozygous or heterozygous for
the Z allele (Table 1), only ﬁve individuals (all PiZZ) showed posi-
tive signals for latent 1-antitrypsin. The latent signals, if present,
were only found in PiZZ individuals with advanced liver ﬁbro-
sis. Comparing the signal intensity and distribution, the latent
signals were much more sparse than the polymer signals, as
observed in the HRP–DAB staining of serial tissue slides (Fig. 5B).
In confocal microscopy, co-localisation of the conformer-speciﬁc
(polymeric or latent) signal was assessed with the non-selective
signal of total 1-antitrypsin stained by a rabbit polyclonal anti-
body (Fig. 5C).
The investigation of liver tissue samples showed there was
abundant staining of polymers in all Z 1-antitrypsin homozy-
gotes and heterozygotes, and there was also staining in an MS
1-antitrypsin heterozygote. The ability of the S variant to form
polymers has previously been shown in secreted material puriﬁed
ex vivo (Elliott et al., 1996). This is the ﬁrst demonstration that S
1-antitrypsin polymers form within liver cells and that they are
recognised by the 2C1 MAb. A polymer score was given to each
sample (Table 1). Since little latent 1-antitrypsin was detected,
the latent signal was  not quantiﬁed but simply denoted as + or −.
There was no more polymer staining in Z 1-antitrypsin homozy-
gotes than heterozygotes. There was  no longitudinal information
available to correlate with accumulation of hepatic 1-antitrypsin
polymers and the development of ﬁbrosis. However, qualitative
analysis showed a spatial association of polymers with ﬁbrotic tis-
sue (Fig. 5A). It may  be that the local production of polymers by the
nodules drives the proliferation of ﬁbroblasts and the deposition
of collagen. In comparison to polymers, little latent 1-antitrypsin
was detected in liver tissues. Trace amounts of latent 1-antitrypsin
were found in liver tissues of PiZZ individuals with advanced ﬁbro-
sis. The observation from both the cell model and human liverwithout extreme stress. Alternatively it may be subject to a highly
effective clearance mechanism that is only compromised in severe
liver disease.
88 L. Tan et al. / The International Journal of Biochemistry & Cell Biology 58 (2015) 81–91
Fig. 5. Distribution patterns of polymeric and latent ˛1-antitrypsin in liver tissues. Samples analysed in immunohistochemistry were from individuals who were not receiving
augmentation therapy. (A) The typical location of polymers. Polymers (PiZZ) were most commonly observed at the periportal zone close to ﬁbrous tissue (left, overview;
right,  magniﬁed detail), suggesting a relationship between polymers and ﬁbrosis. (B) Comparison of polymer and latent 1-antitrypsin staining. Serial slides (PiZZ) were
stained  using HRP–DAB, with the 2C1 (Pol) MAb, 1C12 (Lat) MAb, a non-speciﬁc generic mouse antibody (Ctrl, mouse IgG) and no primary antibody (Ctrl, no IgG). Images
show  an overview (left), magniﬁed details of the positive signals (middle) and the control staining (right, separated by double lines). The presence of latent 1-antitrypsin in
liver  tissues was  rare, whilst there were abundant hepatic polymers. (C) In addition to the HRP–DAB method, tissues were stained by the 2C1 MAb  (and also 1C12 MAb, data
not  shown) and rabbit polyclonal antibody to co-localise the polymeric (Pol; green) and total 1-antitrypsin (Total; red), and examined by confocal microscopy. Exemplary
image  shows a moderate level of polymer staining in a PiZZ sample. (D) There is no staining in the control PiMM individual for polymers (left) or latent 1-antitrypsin (right).
n  = 30 individuals.
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Fig. 6. Plasma polymeric 1-antitrypsin arises endogenously, whilst plasma latent 1-antitrypsin originates from augmentation therapy. (A) The speciﬁcity of the 1C12 MAb
was  conﬁrmed by using it to immunoprecipitate (IP) latent 1-antitrypsin from the plasma of PiZZ individuals with (ZZ(lat+), on augmentation) and without (ZZ(lat−), not
on  augmentation) a positive signal on ELISA. Proteins were transferred from the SDS gel to a membrane and probed with the rabbit polyclonal antibody. (B) The ZZlat(+)
sample was analysed by western blot of an SDS PAGE together with the augmentation therapy. There was no detectable cleaved 1-antitrypsin in plasma or augmentation
therapy. (C) The ZZ(lat+) and ZZ(lat−)  samples, the augmentation therapy and puriﬁed native (Nat) and cleaved (Clv) controls were separated by non-denaturing and urea
PAGE  and subjected to western blot analysis for 1-antitrypsin using a rabbit polyclonal antibody. The western blot of the non-denaturing PAGE conﬁrmed the presence
of  polymers in the ZZ(lat+) sample and in the augmentation therapy (Pol), which was consistent with our previous study (Tan et al., 2014). The western blot of the urea
PAGE  showed the presence of latent 1-antitrypsin in ZZ(lat+) plasma sample and in therapy (arrow, Lat). (D) Levels of the total and latent 1-antitrypsin are plotted for
the  latent-positive samples. At low 1-antitrypsin levels there is no association in the data points (left, circled). This may be due to the limited sensitivity of quantitative
assays at lower protein abundance. At higher 1-antitrypsin levels, a linear correlation is found between latent and total 1-antitrypsin in the plasma of individuals receiving
1-antitrypsin augmentation therapy (right). (E) Levels of latent and total 1-antitrypsin at each time interval of therapy, averaged to the total number of samples assessed
within  the therapy group.
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Table 2
Plasma samples in Cohort I and II.
Cohort I
No. patients Genotype No. latent positive
538 ZZ 63
20  MZ  0
20  SZ 0
5  FZ 0
2  Zmmalton 0
3  Zmheerlen 0
3  SS 0
20  MS  0
200 MM 0
Cohort II
No. patients Genotype No. latent positive
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Table 3
Latent and total 1-antitrypsin (AAT) levels for Cohort II.
Therapy frequency Weekly Fortnightly 3 weeks 4 weeks
Latent positive 21 4 0 0
Total tested 67 20 2 2
Mean latent for positive [g/ml] 49.78 15.24 0.00 0.00
Mean total AAT for positive [g/ml] 1501.06 1103.70 650.00 613.60
polymerisation. Lastly, our ﬁndings have direct translational impli-116 ZZ 25
.5. Circulating polymers arise endogenously, whilst plasma
atent ˛1-antitrypsin originates from augmentation therapy
There is currently no cure for 1-antitrypsin deﬁciency. A treat-
ent for the lack of circulating 1-antitrypsin is augmentation
herapy, in which plasma-puriﬁed 1-antitrypsin is administered
ntravenously. We  have analysed serum samples from individuals
sing Prolastin, Aralast and Zemaira. Prolastin is the most com-
only prescribed augmentation, and was used by all individuals
rom Cohorts I (274 on therapy) and II (116 on therapy) on replace-
ent therapy. In addition we analysed 24 and 33 serum samples
rom individuals on Aralast and Zemaira (Supplement Table 1). Due
o the much smaller sample size and limited access to patient infor-
ation for Aralast and Zemaira, a comparative analysis between the
rugs is not possible. Thus, our substantive analysis focuses on the
arger patient groups (Cohorts I and II) on Prolastin as these gave the
equisite power for clear associations. We  have previously shown
hat all individuals with PiZZ 1-antitrypsin deﬁciency have circu-
ating polymers and that there is a weak correlation between the
oncentration of polymers and the presence of chronic obstructive
ulmonary disease (Tan et al., 2014). We  have also shown poly-
ers were undetectable after 5 days (half-life 30 h), in serial plasma
amples of a PiZZ individual who underwent liver transplantation,
ndicating that serum polymers arise from 1-antitrypsin produced
ithin the liver. The 811 plasma samples from nine genotypes
Cohort I, Table 2) that were used in the previous study were re-
creened for the presence of latent 1-antitrypsin with the 1C12
Ab. The speciﬁcity of 1C12 MAb  was conﬁrmed by using it to
mmunoprecipitate latent 1-antitrypsin from the plasma (Fig. 6A).
he plasma screening using ELISA identiﬁed 63 PiZZ individuals
ith positive signals for latent 1-antitrypsin. 274 of the 538 PiZZ
ndividuals were receiving 1-antitrypsin augmentation therapy.
ll the 63 latent 1-antitrypsin-positive individuals were receiving
1-antitrypsin augmentation, whereas the remaining 264 subjects
ho were not receiving augmentation therapy did not have any
etectable latent 1-antitrypsin in their serum (p < 10−14, 2 test).
hese ﬁndings suggest that the presence of circulating latent 1-
ntitrypsin was associated with the use of augmentation therapy.
urther analysis using western blot of SDS, non-denaturing and
rea PAGE (Fig. 6B and C) conﬁrmed the presence of latent 1-
ntitrypsin in plasma samples and in the therapeutic formulation
f 1-antitrypsin. Notably, augmentation therapy also contained
olymers and the levels of polymers in individuals on therapy were
enerally higher than in those not on therapy (Tan et al., 2014). Our
ndings suggest that circulating polymer originates predominantly
rom endogenous material, whilst circulating latent 1-antitrypsin
riginates from augmentation therapy.Mean latent for all [g/ml] 15.65 2.90 0.00 0.00
Mean total AAT for all [g/ml] 1058.01 829.28 650.00 613.60
Although 63 individuals showed a positive signal for latent
1-antitrypsin, the remaining subjects in the 274 individuals
on augmentation therapy did not show detectable latent 1-
antitrypsin. This may  relate to the time that the protein was
administered or the rate of clearance from the circulation. This
information was  not available in Cohort I and so a further cohort
of 116 PiZZ subjects was investigated (Cohort II, Tables 2 and 3).
In this cohort each blood sample was  taken immediately prior to
the administration of augmentation. The subjects were separated
into four groups based on the frequency with which they received
augmentation: every one, two, three or four weeks. Latent 1-
antitrypsin was  not detected in individuals receiving three or four
weekly dosing; however, a proportion of individuals treated weekly
or biweekly had a positive signal (Table 3). Although an accurate
half-life for latent 1-antitrypsin cannot be determined without
serial blood samples, we estimated the approximate half-life to be
less than a week by comparing average levels in the blood samples.
The concentration of circulating latent 1-antitrypsin correlated
with the level of total 1-antitrypsin in individuals receiving aug-
mentation (Fig. 6D). This further supports the observation that all
circulating latent 1-antitrypsin is exogenous in origin.
The presence of polymeric and latent 1-antitrypsin in com-
mercial preparation of augmentation therapy is consistent with the
observation of polymeric and latent 1-antitrypsin being produced
in cell-free conditions in vitro (Fig. 3). Inclusion of alternative, inac-
tive conformers limits the quality and purity and hence functional
activity of 1-antitrypsin augmentation therapy. The currently
available MAbs and the methodologies developed can be used
to detect and quantify the different inactive protein conformers
in complex biological samples, and to improve the purity of 1-
antitrypsin used in augmentation therapy. They will also be useful
tools to study conformational transitions and to assess ‘on-’ and
‘off-pathway’ effects of novel polymerisation blocking therapies
that are in development.
4. Concluding remarks
Both polymeric and latent 1-antitrypsin were detected dur-
ing in vitro induction of polymerisation. In a cell model of
1-antitrypsin deﬁciency however, polymer but no latent 1-
antitrypsin was detectable. In liver tissues, there was abundant
polymer found in individuals with a range of 1-antitrypsin geno-
types and liver ﬁbrosis. In comparison, little latent 1-antitrypsin
was detected in human liver tissues from PiZZ 1-antitrypsin indi-
viduals with advanced cirrhosis. Polymers were detected in plasma
of all PiZZ individuals, whereas the latent 1-antitrypsin detected in
circulation was  shown to have arisen from the augmentation ther-
apy. These data suggest that the latent conformer is a minor product
of the polymerisation pathway in vivo and that the pathological
polymer is unlikely to be assembled from latent-like protomers
as has been proposed for the C-terminal domain swap model ofcations. Both latent and polymeric conformers of 1-antitrypsin are
produced in industrial preparation of augmentation therapy, which
compromises the purity and effectiveness of the drug. The ability
f Bioch
t
t
C
A
a
B
A
f
2
R
C
C
C
D
D
E
E
E
E
F
G
G
H
I
IL. Tan et al. / The International Journal o
o detect and quantify this using 2C1 and 1C12 MAbs will facilitate
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